- Company List - L
- LHDX
Insider Trading activities at Lucira Health, Inc. (LHDX)
Insider trading activities (stock purchases, sales, and option exercises)
reported by insiders of Lucira Health, Inc. (LHDX)
since 2021 are shown in Table 1 and Table 2.
Table 1 shows the monthly insider trading data of Lucira Health, Inc..
Table 2 shows the detailed insider transactions.
This company's CIK number is 1652724.
Total stock buying since 2021: $58,991,288.
Total stock sales since 2021: $959,846.
Total stock option exercises since 2021: $587,359.
Table 1. Yearly summary of insider stock purchases, sales, and option exercises
at Lucira Health, Inc. (LHDX).
|
Insider Buying |
Insider Sales |
Option Exercises |
| Year |
Shares | Value |
Shares | Value |
Shares | Value |
| 2023 | 0 | $0 | 789,301 | $785,354 | 574,666 | $471,226 |
| 2022 | 60,000 | $141,300 | 93,207 | $174,492 | 0 | $0 |
| 2021 | 3,461,764 | $58,849,988 | 0 | $0 | 103,691 | $116,133 |
Table 2. Monthly summary of insider trading at Lucira Health, Inc. (LHDX).
| Trading Period |
Insider Buying |
Insider Sales |
Option Exercises |
| year-month |
Shares | Value |
Shares | Value |
Shares | Value |
| 2023-03 | 0 | $0 | 784,273 | $783,997 | 574,666 | $471,226 |
| 2023-02 | 0 | $0 | 5,028 | $1,357 | 0 | $0 |
| 2022-12 | 0 | $0 | 4,263 | $682 | 0 | $0 |
| 2022-11 | 0 | $0 | 14,456 | $5,735 | 0 | $0 |
| 2022-09 | 20,000 | $36,400 | 534 | $796 | 0 | $0 |
| 2022-08 | 0 | $0 | 32,654 | $79,506 | 0 | $0 |
| 2022-07 | 0 | $0 | 248 | $624 | 0 | $0 |
| 2022-06 | 10,000 | $14,900 | 1,764 | $2,734 | 0 | $0 |
| 2022-05 | 0 | $0 | 37,109 | $74,218 | 0 | $0 |
| 2022-03 | 30,000 | $90,000 | 2,179 | $10,197 | 0 | $0 |
| 2021-06 | 0 | $0 | 0 | $0 | 103,691 | $116,133 |
| 2021-02 | 3,461,764 | $58,849,988 | 0 | $0 | 0 | $0 |
Table 3. Detailed insider trading at Lucira Health, Inc. (LHDX)
| Trade Date |
Insider Name |
Trade Type |
Shares |
Price ($) |
Value ($) |
| 2023-03-07 | Narido Richard Clavano (Chief Financial Officer) | Sale | 2,382 | .45 | 1,071 |
| 2023-03-07 | Collins Kevin Walter (Chief Revenue Officer) | Sale | 81,717 | .48 | 39,224 |
| 2023-03-06 | Narido Richard Clavano (Chief Financial Officer) | Sale | 1,910 | .57 | 1,088 |
| 2023-03-03 | Narido Richard Clavano (Chief Financial Officer) | Sale | 25,091 | 1.07 | 26,847 |
| 2023-03-03 | Allen Anthony Joseph (Chief Operations Officer) | Sale | 8,405 | 1.00 | 8,405 |
| 2023-03-03 | Collins Kevin Walter (Chief Revenue Officer) | Sale | 30,102 | 1.15 | 34,617 |
| 2023-03-03 | Engelson Erik T. (President and Chief Executive) | Sale | 634,666 | 1.06 | 672,745 |
| 2023-03-03 | Engelson Erik T. (President and Chief Executive) | Option Ex | 574,666 | .82 | 471,226 |
| 2023-02-16 | Kashmolah Ghazi (Ex VP & Chief Quality Officer) | Sale | 5,028 | .27 | 1,357 |
| 2022-12-20 | Allen Anthony Joseph (Chief Operations Officer) | Sale | 4,263 | .16 | 682 |
| 2022-11-27 | Collins Kevin Walter (Chief Revenue Officer) | Sale | 9,666 | .42 | 4,059 |
| 2022-11-16 | Kashmolah Ghazi (Ex VP & Chief Quality Officer) | Sale | 4,790 | .35 | 1,676 |
| 2022-09-18 | George Dan (CFO and Treasurer) | Sale | 343 | 1.38 | 473 |
| 2022-09-15 | Engelson Erik T. (President and Chief Executive) | Buy | 20,000 | 1.82 | 36,400 |
| 2022-09-01 | Mitra Debkishore (Chief Technology Officer) | Sale | 191 | 1.69 | 323 |
| 2022-08-27 | Collins Kevin Walter (Chief Revenue Officer) | Sale | 8,580 | 1.72 | 14,757 |
| 2022-08-25 | Kashmolah Ghazi (Ex VP & Chief Quality Officer) | Sale | 1,500 | 1.93 | 2,895 |
| 2022-08-18 | Kashmolah Ghazi (Ex VP & Chief Quality Officer) | Sale | 3,500 | 2.25 | 7,875 |
| 2022-08-17 | Kashmolah Ghazi (Ex VP & Chief Quality Officer) | Sale | 19,074 | 2.83 | 53,979 |
| 2022-07-08 | Prashar Tamanna (Vice President) | Sale | 248 | 2.52 | 624 |
| 2022-06-18 | George Dan (CFO and Treasurer) | Sale | 1,321 | 1.45 | 1,915 |
| 2022-06-16 | Engelson Erik T. (President and Chief Executive) | Buy | 10,000 | 1.49 | 14,900 |
| 2022-06-01 | Mitra Debkishore (Chief Technology Officer) | Sale | 186 | 1.85 | 344 |
| 2022-06-01 | Prashar Tamanna (Vice President) | Sale | 257 | 1.85 | 475 |
| 2022-05-27 | Collins Kevin Walter (Chief Revenue Officer) | Sale | 37,109 | 2.00 | 74,218 |
| 2022-03-15 | Engelson Erik T. (President and Chief Executive) | Buy | 30,000 | 3.00 | 90,000 |
| 2022-03-01 | Mitra Debkishore (Chief Technology Officer) | Sale | 890 | 4.68 | 4,165 |
| 2022-03-01 | Prashar Tamanna (Vice President) | Sale | 1,289 | 4.68 | 6,032 |
| 2021-06-09 | Prashar Tamanna (Vice President) | Option Ex | 103,691 | 1.12 | 116,133 |
| 2021-02-05 | Boeding Chad (Other) | Buy | 3,461,764 | 17.00 | 58,849,988 |
Insider trading activities including stock purchases, stock sales, and option exercises
of LHDX listed in the above tables cannot be completely guaranteed as to their accuracy.
For more insider trading information of Lucira Health, Inc. (symbol LHDX,
CIK number 1652724) see
the Securities and Exchange Commission (SEC) website.